A phase I study of concurrent weekly carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy as an adjuvant treatment for early-stage cervical cancer patients with positive pelvic lymph nodes

International Journal of Gynecological Cancer

Volumn 23, Issue 7, 2013, Pages 1279-1286

  Mabuchi, Seiji ^a   Takahashi, Ryoko ^a   Isohashi, Fumiaki ^a   Yokoi, Takeshi ^b   Ito, Kimihiko ^c   Tsutui, Tateki ^a   Ogata, Toshiyuki ^a   Yoshioka, Yasuo ^a   Ogawa, Kazuhiko ^a   Kimura, Tadashi ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b Kaizuka Municipal Hospital   (Japan)

^c KANSAI ROSAI HOSPITAL   (Japan)

Author keywords

Carboplatin; Cervical cancer; IMRT; Paclitaxel; Phase i study

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE ESCALATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAXIMUM TOLERATED DOSE; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; PELVIS LYMPH NODE; PELVIS LYMPHADENECTOMY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADICAL HYSTERECTOMY; THROMBOCYTOPENIA; UROGENITAL TRACT DISEASE; UTERINE CERVIX CANCER;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; PELVIC NEOPLASMS; PROGNOSIS; RADIOTHERAPY, INTENSITY-MODULATED; UTERINE CERVICAL NEOPLASMS;

EID: 84884526036     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31829c3e32     Document Type: Article

References (25)

1. Monk BJ, Cha DS, Walker JL, et al. Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma. Gynecol Oncol. 1994;54:4-9.
2. Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606-1613.
3. Okazawa M, Mabuchi S, Isohashi F, et al. The prognostic significance of multiple pelvic node metastases in cervical cancer patients treated with radical hysterectomy plus adjuvant chemoradiotherapy. Int J Gynecol Cancer. 2012;22:490-497.
4. Mabuchi S, Okazawa M, Isohashi F, et al. Postoperative whole pelvic radiotherapy plus concurrent chemotherapy versus extended-field irradiation for early-stage cervical cancer patients with multiple pelvic lymph node metastases. Gynecol Oncol. 2011;120:94-100.
5. Mabuchi S, Okazawa M, Isohashi F, et al. Radical hysterectomy with adjuvant radiotherapy versus definitive radiotherapy alone for FIGO stage IIB cervical cancer. Gynecol Oncol. 2011;123:241-247.
6. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999;17:409-422.
7. Yang LX, Douple EB, O'Hara JA, et al. Production of DNA double-strand breaks by interactions between carboplatin and radiation: A potential mechanism for radiopotentiation. Radiat Res. 1995;143:309-315.
8. Higgins RV, Naumann WR, Hall JB, et al. Concurrent carboplatin with pelvic radiation therapy in the primary treatment of cervix cancer. Gynecol Oncol. 2003;89:499-503.
9. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group study. J Clin Oncol. 2009;27:4649-4655.
10. Tishler RB, Geard CR, Hall EJ, et al. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res. 1992;52: 3495-3497.
11. Cerrotta A, Gardan G, Cavina R, et al. Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose. Eur J Gynaecol Oncol. 2002;23:115-119.
12. Hisamatsu T, Mabuchi S, Yoshino K, et al. Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer. Int J Gynecol Cancer. 2012;22:623-629.
13. Mabuchi S, Morishige K, Fujita M, et al. The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy. Gynecol Oncol. 2009;113:200-204.
14. Kitagawa R. 2012 ASCO annual meeting. J Clin Oncol. 2012;30, (suppl; abstract 5006).
15. de Vos FY, Bos AM, Gietema JA, et al. Paclitaxel and carboplatin concurrent with radiotherapy for primary cervical cancer. Anticancer Res. 2004;24:345-348.
16. Rao GG, Rogers P, Drake RD, et al. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer. Gynecol Oncol. 2005;96:168-172.
17. Kim K, Chie EK, Wu HG, et al. Efficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer. Gynecol Oncol. 2006;101:398-402.
18. Lee MY, Wu HG, Kim K, et al. Concurrent radiotherapy with paclitaxel/carboplatin chemotherapy as a definitive treatment for squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 2007;104:95-99.
19. Higgins R, Bussey M, Naumann W, et al. Concurrent carboplatin and paclitaxel with pelvic radiation therapy in the primary treatment of cervical cancer. Am J Obstet Gynecol. 2007;197:205.e1Y205.e5.
20. Addeo D, Blank S, Muggia F, et al. Concurrent radiotherapy, paclitaxel and dose escalating carboplatin in the treatment of cervical cancerVa phase I study. Anticancer Res. 2008;28:3143-3146.
21. Kim HS, Kim MK, Kim HJ, et al. Phase II study of consolidation chemotherapy after adjuvant or primary concurrent chemoradiation using paclitaxel and carboplatin to treat high-risk early-stage or locally advanced cervical cancer. Cancer Res Treat. 2012;44:97-103.
22. Galvin JM, De Neve W. Intensity modulating and other radiation therapy devices for dose painting. J Clin Oncol. 2007;25: 924-930.
23. Chen MF, Tseng CJ, Tseng CC, et al. Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:1438-1444.
24. Small W Jr, Mell LK, Anderson P, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys. 2008;71:428-434.
25. Consensus guidelines for the delineation of the intensity modulated pelvic radiotherapy CTV in the postoperative treatment of endometrial and cervical cancer. Available at: http://www.rtog.org/CoreLab/ContouringAtlases/ GYN.aspx. Accessed December 10, 2012.